Evidence map›Paper›PMID 38680577›Full record

ReviewAsian journal of urology2024

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with non-metastatic and metastatic prostate cancer: A meta-analysis and systematic review.

Stefano Salciccia, Marco Frisenda, Giulio Bevilacqua, Pietro Viscuso, Paolo Casale, Ettore De Berardinis, Giovanni Battista Di Pierro, Susanna Cattarino, Gloria Giorgino, Davide Rosati and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Asian journal of urology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stefano SalcicciaDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Marco FrisendaDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Giulio BevilacquaDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Pietro ViscusoDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Paolo CasaleDepartment of Urology, Humanitas, 20089 Rozzano, MI, Italy.
Ettore De BerardinisDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Giovanni Battista Di PierroDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Susanna CattarinoDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Gloria GiorginoDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Davide RosatiDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Francesco Del GiudiceDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Alessandro SciarraDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Gianna MariottiDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.
Alessandro GentilucciDepartment of Urology, Sapienza Rome University, Policlinico Umberto I, 00161 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To analyze data available in the literature regarding a possible prognostic value of the platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR) in prostate cancer (PCa) patients stratified in non-metastatic and metastatic diseases. Methods: A literature search process was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. In our meta-analysis, the pooled event rate estimated and the pooled hazard ratio were calculated using a random effect model. Results: Forty-two articles were selected for our analysis. The pooled risk difference for non-organ confined PCa between high and low NLR cases was 0.06 (95% confidence interval [CI]: -0.03-0.15) and between high and low PLR cases increased to 0.30 (95% CI: 0.16-0.43). In non-metastatic PCa cases, the pooled hazard ratio for overall mortality between high and low NLR was 1.33 (95% CI: 0.78-1.88) and between high and low PLR was 1.47 (95% CI: 0.91-2.03), whereas in metastatic PCa cases, between high and low NLR was 1.79 (95% CI: 1.44-2.13) and between high and low PLR was 1.05 (95% CI: 0.87-1.24). Conclusion: The prognostic values of NLR and PLR in terms of PCa characteristics and responses after treatment show a high level of heterogeneity of results among studies. These two ratios can represent the inflammatory and immunity status of the patient related to several conditions. A higher predictive value is related to a high NLR in terms of risk for overall mortality in metastatic PCa cases under systemic treatments.

Indexed as

Meta-analysisMetastaticNeutrophil-to-lymphocyte ratioPlatelet-to-lymphocyte ratioProstatic neoplasmRadical prostatectomy

Identifiers

PMID38680577
PMCPMC11053338

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.